DK3160948T3 - BENZOXAZINONAMIDES AS MODULATORS OF MINERALOCORTICOID RECEPTORS - Google Patents
BENZOXAZINONAMIDES AS MODULATORS OF MINERALOCORTICOID RECEPTORS Download PDFInfo
- Publication number
- DK3160948T3 DK3160948T3 DK15736015.7T DK15736015T DK3160948T3 DK 3160948 T3 DK3160948 T3 DK 3160948T3 DK 15736015 T DK15736015 T DK 15736015T DK 3160948 T3 DK3160948 T3 DK 3160948T3
- Authority
- DK
- Denmark
- Prior art keywords
- benzoxazin
- dihydro
- oxo
- mmol
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462018790P | 2014-06-30 | 2014-06-30 | |
| PCT/GB2015/051860 WO2016001631A1 (en) | 2014-06-30 | 2015-06-26 | Benzoxazinone amides as mineralocorticoid receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3160948T3 true DK3160948T3 (en) | 2019-02-18 |
Family
ID=53539739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15736015.7T DK3160948T3 (en) | 2014-06-30 | 2015-06-26 | BENZOXAZINONAMIDES AS MODULATORS OF MINERALOCORTICOID RECEPTORS |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10017502B2 (OSRAM) |
| EP (1) | EP3160948B1 (OSRAM) |
| JP (1) | JP6368383B2 (OSRAM) |
| KR (1) | KR102012222B1 (OSRAM) |
| CN (1) | CN106536491B (OSRAM) |
| AR (1) | AR101036A1 (OSRAM) |
| AU (1) | AU2015282450C1 (OSRAM) |
| CA (1) | CA2953655C (OSRAM) |
| CY (1) | CY1121596T1 (OSRAM) |
| DK (1) | DK3160948T3 (OSRAM) |
| EA (1) | EA029518B1 (OSRAM) |
| ES (1) | ES2707726T3 (OSRAM) |
| HR (1) | HRP20190147T1 (OSRAM) |
| HU (1) | HUE042370T2 (OSRAM) |
| LT (1) | LT3160948T (OSRAM) |
| ME (1) | ME03316B (OSRAM) |
| MX (1) | MX367404B (OSRAM) |
| PL (1) | PL3160948T3 (OSRAM) |
| PT (1) | PT3160948T (OSRAM) |
| RS (1) | RS58274B1 (OSRAM) |
| SI (1) | SI3160948T1 (OSRAM) |
| SM (1) | SMT201900039T1 (OSRAM) |
| TR (1) | TR201900659T4 (OSRAM) |
| TW (1) | TWI677498B (OSRAM) |
| UY (1) | UY36195A (OSRAM) |
| WO (1) | WO2016001631A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2707726T3 (es) * | 2014-06-30 | 2019-04-04 | Astrazeneca Ab | Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides |
| PE20210644A1 (es) | 2018-07-19 | 2021-03-23 | Astrazeneca Ab | METODOS DE TRATAMIENTO DE HFpEF EMPLEANDO DAPAGLIFLOZINA Y COMPOSICIONES QUE COMPRENDEN LA MISMA |
| CN112107568B (zh) * | 2019-06-19 | 2022-03-25 | 北京龙嘉博创医药科技有限公司 | 二芳基酰胺类化合物及其应用 |
| CR20200224A (es) * | 2019-08-30 | 2021-05-26 | Astrazeneca Ab | Composiciones y métodos de tratamiento de la insuficiencia cardiaca con fracción de eyección reducida con dapagliflozina |
| WO2022022865A1 (en) | 2020-07-27 | 2022-02-03 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
| MX2023015144A (es) * | 2021-06-15 | 2024-01-22 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Derivados de benzoxazinona. |
| TW202409023A (zh) | 2022-07-14 | 2024-03-01 | 美商富曼西公司 | 除草苯并𠯤 |
| CR20250112A (es) | 2022-09-01 | 2025-08-18 | Aztrazeneca Ab | Combinación de ihnibidores de sglt2 y moduladores del receptor mineralcorticoide para usar en el tratamiento de enfermedades cardiorrenales |
| WO2024125591A1 (zh) * | 2022-12-15 | 2024-06-20 | 正大天晴药业集团股份有限公司 | 苯并恶嗪酮类化合物的结晶及其制备 |
| WO2025111184A1 (en) | 2023-11-21 | 2025-05-30 | Fmc Corporation | Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004528335A (ja) * | 2001-04-23 | 2004-09-16 | アストラゼネカ アクチボラグ | 血管新生の治療に使用のベンゾオキサジノン誘導体 |
| JP2006512357A (ja) * | 2002-12-20 | 2006-04-13 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Ｐｉ３ｋの阻害剤としてのベンゾキサジンおよびその誘導体 |
| JP2008506689A (ja) * | 2004-07-14 | 2008-03-06 | リガンド・ファーマシューティカルズ・インコーポレイテッド | 細胞間受容体のモジュレーター化合物および方法 |
| WO2006015259A2 (en) | 2004-07-28 | 2006-02-09 | Irm Llc | Compounds and compositions as modulators of steroid hormone nuclear receptors |
| WO2007077961A2 (en) | 2005-12-28 | 2007-07-12 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds and their use as mineralocorticoid receptor ligands |
| TWI385161B (zh) | 2006-02-02 | 2013-02-11 | Mitsubishi Tanabe Pharma Corp | 含氮雜雙環化合物 |
| GEP20115239B (en) | 2006-10-31 | 2011-06-10 | Pfizer Prod Inc | Pyrazoline compounds as mineralocorticoid receptor antagonists |
| DE102007009494A1 (de) | 2007-02-27 | 2008-08-28 | Bayer Healthcare Ag | Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung |
| CA2681134A1 (en) | 2007-03-23 | 2008-10-02 | Merck & Co., Inc. | Mineralocorticoid receptor modulators |
| KR101477579B1 (ko) | 2007-04-09 | 2014-12-30 | 다이이찌 산쿄 가부시키가이샤 | 피롤 유도체의 아트로프 이성체 |
| JP5173653B2 (ja) * | 2007-08-01 | 2013-04-03 | 田辺三菱製薬株式会社 | 医薬組成物 |
| US8258131B2 (en) | 2007-08-01 | 2012-09-04 | Mitsubishi Tanabe Pharma Corporation | Fused bicyclic compound |
| TWI431010B (zh) | 2007-12-19 | 2014-03-21 | Lilly Co Eli | 礦皮質素受體拮抗劑及使用方法 |
| UY31905A (es) * | 2008-06-18 | 2010-01-29 | Astrazeneca Ab | Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones. |
| US20100094000A1 (en) | 2008-09-03 | 2010-04-15 | Takeda Pharmaceutical Company Limited | Pyrazole compounds |
| WO2010098286A1 (ja) | 2009-02-25 | 2010-09-02 | 第一三共株式会社 | ミネラルコルチコイド受容体拮抗薬を含有する医薬 |
| BRPI1009257A2 (pt) | 2009-03-12 | 2016-03-08 | Lilly Co Eli | antagonista receptor de mineralocorticoide e métodos de uso. |
| EP2417121A1 (en) | 2009-04-10 | 2012-02-15 | Pfizer Inc. | 4, 5-dihydro-1h-pyrazole compounds and their pharmaceutical uses |
| EP2569576B1 (en) | 2010-05-11 | 2016-07-06 | Koninklijke Philips N.V. | Lighting module |
| JP2013528598A (ja) | 2010-05-11 | 2013-07-11 | ファイザー・インク | ミネラルコルチコイド受容体拮抗薬としてのモルホリン化合物 |
| TW201216957A (en) | 2010-07-13 | 2012-05-01 | Dainippon Sumitomo Pharma Co | Biarylamide derivative or a pharmaceutically acceptable salt thereof |
| JP2013542255A (ja) | 2010-11-10 | 2013-11-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ミネラルコルチコイド受容体アンタゴニストとしてのピリジル尿素 |
| ES2707726T3 (es) * | 2014-06-30 | 2019-04-04 | Astrazeneca Ab | Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides |
-
2015
- 2015-06-26 ES ES15736015T patent/ES2707726T3/es active Active
- 2015-06-26 CA CA2953655A patent/CA2953655C/en active Active
- 2015-06-26 MX MX2017000183A patent/MX367404B/es active IP Right Grant
- 2015-06-26 KR KR1020177002518A patent/KR102012222B1/ko active Active
- 2015-06-26 HR HRP20190147TT patent/HRP20190147T1/hr unknown
- 2015-06-26 HU HUE15736015A patent/HUE042370T2/hu unknown
- 2015-06-26 RS RS20190085A patent/RS58274B1/sr unknown
- 2015-06-26 EA EA201790046A patent/EA029518B1/ru not_active IP Right Cessation
- 2015-06-26 LT LTEP15736015.7T patent/LT3160948T/lt unknown
- 2015-06-26 CN CN201580035032.8A patent/CN106536491B/zh active Active
- 2015-06-26 UY UY0001036195A patent/UY36195A/es not_active Application Discontinuation
- 2015-06-26 ME MEP-2019-19A patent/ME03316B/me unknown
- 2015-06-26 WO PCT/GB2015/051860 patent/WO2016001631A1/en not_active Ceased
- 2015-06-26 US US15/320,379 patent/US10017502B2/en active Active
- 2015-06-26 PL PL15736015T patent/PL3160948T3/pl unknown
- 2015-06-26 TR TR2019/00659T patent/TR201900659T4/tr unknown
- 2015-06-26 EP EP15736015.7A patent/EP3160948B1/en active Active
- 2015-06-26 SI SI201530572T patent/SI3160948T1/sl unknown
- 2015-06-26 PT PT15736015T patent/PT3160948T/pt unknown
- 2015-06-26 DK DK15736015.7T patent/DK3160948T3/en active
- 2015-06-26 JP JP2016575499A patent/JP6368383B2/ja active Active
- 2015-06-26 SM SM20190039T patent/SMT201900039T1/it unknown
- 2015-06-26 AU AU2015282450A patent/AU2015282450C1/en active Active
- 2015-06-29 TW TW104120998A patent/TWI677498B/zh active
- 2015-06-29 US US14/753,239 patent/US9394291B2/en active Active
- 2015-06-30 AR ARP150102098A patent/AR101036A1/es active IP Right Grant
-
2019
- 2019-01-24 CY CY20191100097T patent/CY1121596T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3160948T3 (en) | BENZOXAZINONAMIDES AS MODULATORS OF MINERALOCORTICOID RECEPTORS | |
| JP7168773B2 (ja) | イソインドリン化合物、その調製方法、医薬組成物および使用 | |
| AU2016299484B2 (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| JP5564036B2 (ja) | ヒストン脱アセチル化酵素阻害薬としてのスピロ環誘導体 | |
| JP6211530B2 (ja) | 含窒素複素環化合物 | |
| KR101738866B1 (ko) | 안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n'-다이아릴티오우레아 및 n,n'-다이아릴우레아, 이의 제조방법 및 이의 용도 | |
| CA3133753A1 (en) | Novel small molecule inhibitors of tead transcription factors | |
| CN115087440A (zh) | Trpml调节剂 | |
| KR20180016485A (ko) | 무스카린성 m2 수용체의 양성 알로스테릭 조정제 | |
| EP2194051B1 (en) | Process for preparing compounds useful as intermediates for the preparation of modulators of chemokine receptor activity | |
| CN105073724A (zh) | 作为钾离子通道抑制剂的2,3-二氮杂萘类化合物 | |
| Hu et al. | Novel piperazine urea derivatives as highly potent transient receptor potential vanilloid 1 (TRPV1) antagonists | |
| AU2019230859B2 (en) | Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof | |
| EP2501233B1 (en) | Quinazoline compounds | |
| CZ281714B6 (cs) | Piperidylmethylsubstituované deriváty chromanu | |
| HK1237338B (en) | Benzoxazinone amides as mineralocorticoid receptor modulators | |
| HK1237338A1 (en) | Benzoxazinone amides as mineralocorticoid receptor modulators | |
| EP2470022A1 (en) | Compounds and methods | |
| KR20170106483A (ko) | 테트라히드로피라닐 벤즈아미드 유도체 |